Silo Pharma Inc (SILO) News

Form 8-K - Current report

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

IND submission for intranasal SPC-15 treatment expected in 2025; Phase 1 clinical trial to follow upon...

Form 8-K - Current report

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Key preclinical milestone for novel, non-opioid extended-release pain therapeutic   SARASOTA, FL, Dec. 18...

Form 4 - Statement of changes in beneficial ownership of securities

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

Prototype development and feasibility testing underway for optimized subcutaneous delivery SARASOTA, FL, Nov...

Form 4 - Statement of changes in beneficial ownership of securities

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in...

Form DEFR14A - Revised definitive proxy soliciting materials

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

The implant demonstrates stability and consistent drug release, supporting further analytical testing and...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material